

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant



D0273 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV304415443US
Express Mail Label NumberMay 16, 2007
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1656

FEI HUANG, ET AL.

EXAMINER: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: 08/26/2003

FOR: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING
ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR
MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN
TYROSINE KINASE PATHWAYS IN BREAST CELLS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT ACCOMPANYING AN RCE

Sir:

This paper is being filed concurrently with an RCE application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the reference cited on the attached form PTO-1449.

In accordance with 37 C.F.R. § 1.98(a)(2)(iii), applicants wish to call the Examiner's attention to the following related application:



Attorney Docket No.	Application No.	Filing Date	Status
10719 PCT	PCT/US2006/060776	11/10/2006	Pending

SHERIDAN SWOPE, PH.D.
PRIMARY EXAMINER

JAN 26 2008